Our Science
Our Programs
About Us
Newsroom
Careers
Contact
More
Axial Therapeutics Doses First Subjects in Global Phase 2b Clinical Trial for Irritability Associated with Autism Spectrum Disorder (ASD)
Axial Therapeutics Receives FDA Clearance of IND Application and Initiates Phase 2b Trial for AB-2004, Lead Gut-Targeted, Molecular Therapeutic for the Treatment of Irritability in Autism Spectrum Disorder
Axial Therapeutics Raises $37.25 Million in Series C Financing to Advance its Pipeline of Gut-Targeted Small Molecule Drugs for Neurological Diseases and Disorders
Axial Therapeutics to Present at Virtual Jefferies Microbiome-based Therapeutics Summit
Axial Therapeutics Promotes A. Stewart Campbell to Chief Executive Officer
Axial Therapeutics to Present at the Inaugural Virtual H.C. Wainwright BioConnect Conference
